Clinical Trial for Pancreatic Ductal Adenocarcinoma Detection to Commence

Researchers at the University of [Blank] have been conducting a clinical trial to assess the effectiveness of [àü¹F]FAPI-74 PET/CT in detecting metastatic pancreatic ductal adenocarcinoma. The trial, which aims to recruit 200 participants from the USA, is currently not open for recruiting. The study will evaluate the sensitivity and specificity of the PET/CT scan in detecting metastatic disease in adults with pancreatic ductal adenocarcinoma.

Key Takeaways:

• The clinical trial is a Phase 3, interventional study designed to assess the diagnostic performance of [àü¹F]FAPI-74 PET/CT in the detection of metastatic disease in adults with pancreatic ductal adenocarcinoma.
• The study will enroll 200 participants from the USA and will be conducted at multiple sites.
• The primary objective of the trial is to evaluate the sensitivity and specificity of [àü¹F]FAPI-74 PET/CT using a composite SOT panel.
• The trial will involve standardized administration of [àü¹F]FAPI-74 PET/CT and will capture both SOC procedures and interventions for 3 months after injection.
• Participants will be followed-up for safety for 24 to 72 hours after the dose of [àü¹F]FAPI-74 PET/CT.

Statistics:

• The maximum expected duration of the trial is approximately 24 months from first patient screening to last patient SOC follow-up.
• The trial aims to recruit 200 participants from the USA.
• The study will be conducted at multiple sites.
• The trial will evaluate the sensitivity and specificity of [àü¹F]FAPI-74 PET/CT using a composite SOT panel.

Sources:

Source: ClinicalTrials.gov

ID: NCT07217717

Note: The provided text does not include a specific university or researcher, but mentions ClinicalTrials.gov and a study ID.